Aurinia Pharmaceuticals Inc. (AUPH) Receives Buy Rating from Canaccord Genuity
Canaccord Genuity reaffirmed their buy rating on shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) in a research report released on Saturday. The firm currently has a $10.00 target price on the stock.
Several other equities research analysts have also weighed in on AUPH. HC Wainwright assumed coverage on shares of Aurinia Pharmaceuticals in a report on Thursday, June 30th. They issued a buy rating and a $7.00 target price on the stock. Leerink Swann reiterated an outperform rating and issued a $7.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 6th. Finally, FBR & Co restated an outperform rating and set a $9.00 price objective on shares of Aurinia Pharmaceuticals in a report on Tuesday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $7.75.
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 4.70 on Friday. The company has a 50-day moving average of $2.45 and a 200-day moving average of $2.78. The company’s market capitalization is $165.84 million. Aurinia Pharmaceuticals has a one year low of $1.42 and a one year high of $5.69.
An institutional investor recently raised its position in Aurinia Pharmaceuticals stock. Lombard Odier Asset Management USA Corp increased its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 2.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 102,294 shares of the company’s stock after buying an additional 2,813 shares during the period. Lombard Odier Asset Management USA Corp owned 0.29% of Aurinia Pharmaceuticals worth $283,000 as of its most recent SEC filing. Institutional investors and hedge funds own 20.04% of the company’s stock.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.